ISSN Print: 0892-0915
Archives: Volume 10, 1996 to Volume 20, 2008
Volumes:Volume 20, 2008 Volume 19, 2007 Volume 19, 2007 Volume 18, 2006 Volume 17, 2005 Volume 17, 2005 Volume 17, 2005 Volume 16, 2004 Volume 16, 2004 Volume 16, 2004 Volume 15, 2003 Volume 15, 2003 Volume 15, 2003 Volume 14, 2000 Volume 14, 2000 Volume 14, 2000 Volume 12, 1998 Volume 12, 1998 Volume 12, 1998 Volume 11, 1997 Volume 11, 1997 Volume 11, 1997 Volume 10, 1996 Volume 10, 1996 Volume 10, 1996
Critical Reviews™ in Neurobiology
Neuroprotective and Neurotrophic Actions of the Mood Stabilizer Lithium: Can It Be Used to Treat Neurodegenerative Diseases?
Molecular Neurobiology Section, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
The mood stabilizing drug lithium has emerged as a robust neuroprotective agent in preventing apoptosis of neurons. Long-term treatment with lithium effectively protects primary cultures of rat brain neurons from glutamate-induced, NMDA receptor-mediated excitotoxicity. This neuroprotection is accompanied by an inhibition of NMDA-receptormediated calcium influx, upregulation of anti-apoptotic Bcl-2, downregulation of pro-apoptotic p53 and Bax, and activation of cell survival factors. Lithium treatment antagonizes glutamate-induced activation of c-Jun-N-terminal kinase (JNK), p38 kinase, and AP-1 binding, which has a major role in cytotoxicity, and suppresses glutamate-induced loss of phosphorylated cAMP responsive element binding protein (CREB). Lithium also induces the expression of brain-derived neurotrophic factor (BDNF) and subsequent activation TrkB, the receptor for BDNF, in cortical neurons. The activation of BDNF/TrkB signaling is essential for the neuroprotective effects of this drug. In addition, lithium stimulates the proliferation of neuroblasts in primary cultures of CNS neurons.
|Begell Digital Portal||Begell Digital Library||eBooks||Journals||References & Proceedings||Research Collections|